Identification of potentially new anti-infectives against Helicobacter pylori by repurposing FDA-approved drugs

Helicobacter pylori is the most prevalent infection worldwide and the main risk factor for gastric cancer development. Current therapy consists in the use of a combination of antibiotics and a proton pump inhibitor, which has led an alarming increase in antibiotic resistant strains. For this reason, the identification of new, effective drugs for the treatment of this widespread infection is crucial.

In this project, we aim at identifying novel therapies against H. pylori by screening FDA approved substances. After establishing a robust platform for drug repurposing, we identified some compounds with anti-H. pylori properties that we will further characterize in vitro and in vivo.